BluGlass to collaborate with Coherent
Australian firm BluGlass has entered into an early-stage collaboration with photonics giant Coherent Corp to co-develop a novel GaN-based device targeting scientific and medical markets. This initial feasibility study is expected to run for three to five months and will evaluate the compatibility of the companies’ proprietary processes.
Valued at $200k, the collaboration combines BluGlass' complementary expertise in proprietary GaN epitaxial growth and semiconductor laser development with Coherent's leadership in photonics, advanced manufacturing, and market access. Under the agreement, the companies will jointly evaluate device architectures and manufacturing techniques to enable high-performance visible wavelength lasers for demanding scientific instrumentation and medical applications. Initial development discussions have commenced, including device architecture options, epitaxial structure designs, and process integration.
BluGlass CEO Jim Haden said: "Coherent's decision to collaborate with BluGlass is a strong vote of confidence in our GaN epitaxy and laser capabilities, reinforcing our growing industry reputation for developing differentiated technology solutions to support next-generation applications.
”While the initial phase of this collaboration focuses on advancing a novel device architecture, it has the longer- term potential to address high-value opportunities in scientific and medical applications. The collaboration with this industry leader expands our GaN laser portfolio and, more importantly, extends our reach into key scientific and medical markets that demand precision photonic performance.”
